Citius Oncology Inc (CTOR)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Citius Oncology Inc Stock (CTOR) Company Profile

Citius Oncology Inc

Healthcare (1064)

(908) 967-6677

11 COMMERCE DRIVE, CRANFORD

Nächster Verdiensttermin

Neueste SEC-Einreichungen

CTOR's Discussions on Twitter

Compare CTOR vs TAK, TEVA, HLN, ZTS, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CTOR Citius Oncology Inc	0.95	111.05M	5.61M	-42.51M	-16.86M	-0.466
TAK Takeda Pharmaceutical Co Adr	17.86	60.23B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	39.53	45.71B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	8.80	40.72B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	69.69	29.36B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	541.70	20.39B	3.17B	1.29B	1.01B	27.09

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-09-23	Hochstufung	Maxim Group	Hold → Buy
2024-11-27	Eingeleitet	Maxim Group	Buy

Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten

Finanzdaten der Citius Oncology Inc-Aktie (CTOR)

Citius Oncology Inc (CTOR)

Citius Oncology Inc Stock (CTOR) Company Profile

Compare CTOR vs TAK, TEVA, HLN, ZTS, UTHR

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten

Citius Oncology Announces Results of 2026 Annual Stockholder Meeting Votes - kalkinemedia.com

Citius Oncology Shareholders Approve Directors and Auditor - TipRanks

Citius Oncology (CTOR) Ticks Higher: Shares Climb 2.39% to $1.07 Near Key ResistanceMomentum Stock Picks - siam.in

CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill

CTXR Stock Price, Quote & Chart - ChartMill

Citius Pharmaceuticals at Moody Capital conference: launch gains traction By Investing.com - Investing.com UK

Citius Pharma CEO to speak at two New York conferences - Stock Titan

Citius Pharmaceuticals to Participate in September 2026 Investor Conferences - Yahoo Finance

Citius Oncology (CTOR) Slips 1.86% to $0.78 as Shares Press Against Key Support ZoneBPI Bull Confirmed - dars.gov.et

CITIUS ONCOLOGY, INC. SEC Filing (Aug 26, 2026) - Stock Titan

Citius (CTOR) Quarterly Results: The EPS Result Is Below Expectation in the Latest Session; Session Move: Shares Finish 2.02% Lower on the DayEPS Surprise History - vinanet.vn

Enterprise value to EBIT forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView

Armistice Capital Expands Citius Oncology (CTOR) Stake Despite Distress Signals - GuruFocus

Citius (CTOR) Quarterly Results: Reported EPS Misses Expectations in the Reported Period; After Results: The Market Price Advances 6.97% on the DayForward Guidance Trends - vinanet.vn

Citius Oncology Shares Slide 10% After Fiscal Q3 Revenue Misses Estimates Despite LYMPHIR Launch Gains - dars.gov.et

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum - Yahoo Finance

Citius Oncology stock tumbles 10% on revenue miss despite launch progress - Investing.com Australia

Citius Oncology (CTOR) Institutional Ownership 2026 $CTOR - MarketBeat

Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination - The Clinical Trial Vanguard

CTOR Q2 2026 Earnings: Pre-Revenue Loss Misses Badly, Yet Shares Jump 10%EBITDA Analysis - vinanet.vn

Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR) - simplywall.st

Citius Pharma Reports First LYMPHIR Revenue of $7.1M in Nine Months - Minichart

Citius Oncology Posts First Revenue from LYMPHIR Launch as Institutional Demand Surges 31% - Minichart

Citius Oncology (NASDAQ:CTOR) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat

Citius Oncology (CTOR) director Jonathan Peri files Form 3 showing no common shares - Stock Titan

Citius Pharma Q3 EPS beats estimate, sales miss by 72% - scanx.trade

Citius Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress - Intellectia AI

CTOR: LYMPHIR launch drove $7.1M revenue and 31% sequential vial order growth, with broad payer access - TradingView

Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss - Stock Titan

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - PR Newswire

Citius Oncology (CTOR) Advances 5.5% to $0.87 as Buyers Defend Support ZoneInverse ETF Flow - vinanet.vn

Citius Oncology (CTOR) investor reports 9.99% beneficial ownership stake - Stock Titan

Citius Oncology | 3: Initial statement of beneficial ownership of securities- Peri Jonathan - Moomoo

Citius Oncology appoints independent director Peri to board of directors - ROI-NJ

Citius Oncology appoints Jonathan Peri to board of directors By Investing.com - Investing.com Australia

People on the Move: Jonathan Peri, Ph.D., J.D., Joins Citius Oncology’s Board of Directors - BioBuzz

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - Morningstar

Citius Pharmaceuticals expands Citius Oncology board to nine with appointment of Jonathan Peri - Traders Union

Form 8K Citius Oncology Inc For: 12 August By Investing.com - Investing.com South Africa

Citius Oncology adds independent director to expanded board - TipRanks

Citius Oncology Adds Jonathan Peri to Board as LYMPHIR Commercialization Advances - citybiz

Citius Oncology appoints Jonathan Peri to board of directors - Investing.com

Citius Oncology (CTOR) Expected to Announce Earnings on Tuesday - MarketBeat

Citius Oncology Inc (CTOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Citius Oncology Inc expected to post a loss of 5 cents a shareEarnings Preview - TradingView

CTOR Q2 2026 Earnings: Deep EPS Miss Highlights Development-Stage Cash Burn ChallengesDividend Earnings Report - vinanet.vn

Citius Oncology of Cranford says commercial response to cancer treatment is strong - ROI-NJ

LYMPHIR orders rise 78% QoQ as Citius Oncology expands market access for CTCL treatment. - Pluang

Citius Oncology reports strong LYMPHIR U.S. launch momentum - TipRanks

Citius Oncology reports strong LYMPHIR commercial momentum - TipRanks

Finanzdaten der Citius Oncology Inc-Aktie (CTOR)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie CTOR